the 6 agencies (9 publications) that evaluated DPP-4 inhibitors, 2 recommended the drug not be listed or funded (CADTH, AHTAPol) and 4 recommended restricted use (PBAC, SMC, CVZ and NICE). The most common reason for agency's disinclination for listing/funding was insufficient information on the effectiveness and cost-effectiveness in the specified patient population. There are more than 100 HTAs ongoing in the endocrine nutritional and metabolic therapeutic area, approximately half of them (49 projects) concern diabetes, 21 of which evaluate pharmacological treatment of diabetes (8 countries, 11 agencies). CONCLUSIONS: Diabetes prevalence is on the rise, attracting increasing attention from health care agencies. Despite using similar data sources variable outcomes suggest to us that agencies are applying different weightings in their assessment process. The apparent failure to demonstrate effectiveness in specified populations suggests late segmentation by manufacturers and insufficient resourcing to generate data. This is often due to late payer requests for such analyses motivated by financial considerations. Early segmentation and engagement with payers is thus critical for HTA success.
PDB77 BASELINE CHARACTERISTICS OF PATIENTS BEGINNING BASAL, BASAL PLUS SHORT-ACTING, SHORT-ACTING OR PREMIX INSULIN:
DATA FROM THE CREDIT STUDY Home P 1 , Blonde L 2 , Marre M 3 , Admane K 4 , Vespasiani G 5 1 Newcastle University, Newcastle upon Tyne, UK, 2 Ochsner Medical Center, New Orleans, LA, USA, 3 Université Paris, INSERM U695, Paris, France, 4 Sanofi-Aventis, Paris, France, 5 Diabetology and Metabolic Disorders Centre, Ascoli Piceno, San Benedetto del Tronto, Italy OBJECTIVES: The ongoing Cardiovascular (CV) Risk Evaluation in people with Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is assessing the effect of insulin on the risk of vascular events. METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North America, Europe and Asia, and includes 3031 people with T2DM who recently started basal and/or short-acting insulin, premix insulin or another insulin type. This analysis examines and compares the characteristics between groups starting basal (n 1563), basal short-acting (n 444), shortacting (n 221), premixed (n 700) or another (n 103) insulin. RESULTS: Demographic and diabetes characteristics were reasonably balanced between the insulin groups, although those receiving basal plus short-acting insulin or premix had a trend to higher baseline HbA1c levels vs other insulin types (basal, 9.2 1.8%; basal short-acting, 10.1 2.2%; short-acting, 9.4 2.0%; premix, 9.9 2.0%; other, 9.1 2.0%). While the majority had previously used oral glucose lowering drugs (OGLDs) (basal, 97%; basal short-acting, 83%; short-acting, 83%; premix, 94%; other, 85%), differences in the numbers continuing OGLDs when beginning insulin were found. Continued use of OGLDs was highest wth basal insulin (89%) versus the other insulins (basal short-acting, 36%; short-acting, 45%; premix, 62%; other, 34%). However, the distribution of types of OGLD used before insulin was similar between the groups. There are no clear patterns in CV risk profile by insulin type. Previous diagnosis of hypertension (basal, 71%; basal short-acting, 65%; short-acting, 57%; premix, 69%; other, 72%), family history of CV disease (basal, 29%; basal shortacting, 25%; short-acting, 21%; premix, 23%; other, 14%) and body mass index tended to be lower in the short-acting insulin group. However, triglyceride levels were lower in the short-acting and 'other' insulin groups vs premix, basal and basal plus short-acting groups. Here we report variation in baseline characteristics of participants in eastern vs northern vs southern Europe. RESULTS: Marked differences in participant characteristics were found between eastern Europe (n 735), northern (n 460) and southern Europe (n 647), including proportion of males (25 vs. 61 vs. 56%), diabetes duration (8 5 vs. 9 6 vs. 13 9 years), age (58 8 vs. 63 11 vs. 63 11 years) and HbA1c (9.7 1.9 vs. 9.1 2.0 vs. 9.3 1.9%). Combinations of oral glucose-lowering drugs were common before insulin; sulfonylureas were dominant in eastern Europe and metformin elsewhere. Over 80% were taking nonglucose medications before insulin initiation, most commonly ARBs. People in eastern Europe had a greater family history of CV disease, were less physically active, but were not more obese (BMI: 30.7 5.4 vs. 31.5 6.3 vs. 29.6 5.9 kg/m 2 ). Rates of hypertension were lowest in southern Europe. HDL cholesterol in males was lowest in northern Europe and in females was highest in eastern Europe. LDL cholesterol was highest in southern Europe. Total cholesterol levels were lowest, but triglyceride levels were highest in northern Europe. Smoking was less prevalent in eastern Europe. Most people began with a basal insulin regimen (60 vs 63 vs. 62%); more people used meal-time insulin in eastern Europe (19 vs. 11 vs. 17%) and pre-mixes in northern Europe (22 vs. 28 vs. 13%). CONCLUSIONS: Baseline characteristics of people starting insulin reveals some striking differences between European regions; how these translate into CV events as the study progresses will be of interest. The Cardiovascular Risk Evaluation in people with Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is evaluating the effect of insulin on the risk of vascular events, which can be reduced via long-term glycaemic control. METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North America, Europe and Asia. It includes 3031 people with T2DM who had recently started basal, short-acting or premix insulin, over half of whom received basal insulin alone (n 1563). This analysis examines the baseline characteristics amongst the subgroup initiating basal insulin after oral failure and compares them with those of the wider CREDIT population. RESULTS: The mean starting dose of basal insulin was 14.7 IU/day, administered once daily in 86% of participants. Of these, 61% took their injection at bedtime, 21% at breakfast, 17% at dinner and 1% at lunch. Over 90% used pen devices, split equally between disposable (46%) and reusable devices (45%). Demographic and clinical characteristics, including macrovascular disease and cardiovascular risk profiles, were broadly similar between the basal insulin subgroup and the overall group of participants (basal insulin subgroup vs total population: males, 48 vs 51%; age, 62 11 vs 61 10 years; T2DM duration, 10 7 vs 11 8 years; HbA1c, 9.2 1.8 vs 9.5 2.0%; prior use of oral glucose lowering drugs [OGLDs], 97 vs 93%). Use of OGLDs with insulin tended to be higher in the basal insulin subgroup than in the total population (any OGLD, 89 vs. 70%; biguanides, 64 vs. 50%, sulfonylureas, 63 vs. 43%). CONCLUSIONS: The one notable difference between the groups was that those beginning basal insulin alone were more heavily treated with OGLDs beforehand than in the overall population, most commonly biguanides and sulfonylureas. This suggests that they required no lesser intensity of glycaemic management than people starting on other types of insulin. and 97.9% (10.8 from 11) for DM20 and DM07 respectively. Mean HbA1c of 6.9 (standard deviation 1.5; 1-2 years after entry to study) was taken from UKPDS 56. 252 HbA1c values (average diabetes QOF register) were generated from this distribution and percentage achievement of current and proposed indicators was calculated. This simulation was repeated 8,294 times (number of QOF practices) and average achievement for each indicator was noted. RESULTS: Average achievement of current indicators using UKPDS 56 distribution was estimated at 65.5% and 98.1% for DM20 and DM07 respectively, comparing favourably with reported results. Average achievement of proposed QOF indicators was estimated at 52.7%, 76.8% and 91.9% with maximum points (35 in total) awarded at 50%, 70% and 90% for DM23, DM24 and DM25 respectively. CONCLUSIONS: Although the QOF targets for HbA1c are lower, the average percentage achievement is estimated to reach the level required for maximum QOF points. However, since the average is close to the maximum payment level for DM23 and DM25 a number of practices are unlikely to reach this unless increased reductions in HbA1c are achieved.
PDB79 DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COMPARED WITH THE OVERALL POPULATION IN THE

PDB80 MEASURING GLYCOSYLATED HAEMOGLOBIN LEVELS IN PATIENTS WITH DIABETES: IMPACT OF LOWER QOF TARGETS ON ACHIEVEMENT OF CLINICAL INDICATORS AND QOF POINTS
PDB81 THE ROAD TO INSULIN-A PATH OF TREATMENT ANALYSIS OF REAL-WORLD PHARMACY DATA FROM THE USA
Christensen TE 1 , Thomsen TL 1 , Bouchard JR 2 , Seligman R 3 , Hamlin D 3 1 Novo Nordisk A/S, Virum, Denmark, 2 Novo Nordisk, Inc., Princeton, NJ, USA, 3 SDI Health, Boston, NY, USA OBJECTIVES: Understanding current and new paths of treatment (POT) in diabetes is pivotal for estimating budget impacts when new antidiabetic agents are introduced to pharmacy formularies. Although diabetes treatment guidelines exist to guide prescribers, very limited real-life data are available to illuminate actual POT's for patients initiating insulin treatment. The aim of this study was to establish the most prevalent POT's for insulin initiation using real-world US pharmacy data. METHODS: Medicaid, Cash and 3 rd party payer pharmacy claims were obtained from SDI. A patient's first insulin Rx between October and December. 2004 served as an index Rx. A 6 month look-back identified prior treatments and a 3 year look-forward tracked changes from the index Rx. To be eligible for analysis, patients had to have no insulin Rx in the look-back and be in the SDI database in the first and last quarter of observation. The pattern of payers and prescribers were identified along with the most frequent Rx combinations for each step. The average duration for each step was analyzed. RESULTS: Out of 351,887 patients with an index insulin Rx, 78,213 had no insulin in the look-back. Claims were paid by Medicaid (13%), cash (4%), and 3 rd party (83%). The top-10 combinations prior to the index insulin constituted 96% of the data. The top 3 were Metformin(MET) Sulfonylurea(SU) (18%), Met alone (17%) and SU alone (13%). The top-10 combinations initiating index insulin constituted 59% of the data. The top 3 were MET SU basal insulin (11%), MET SU TZD basal insulin (11%), and SU basal insulin (6%). On average, patients initiating insulin went 230 days without changing their therapy. CONCLUSIONS: Based on real-world US data, a small number of therapy combinations explain the POT's before insulin initiation. Upon initiating insulin treatment, combinations are more varied, although most include basal insulin. Enfuvirtide is part of a novel class of agents known as fusion inhibitors approved following the phase III TORO trials. The objective of ZOOM cohort was to assess in real life setting long term efficacy and safety of enfuvirtide in HIV-1 patients. METHODS: ZOOM is a multicenter, observational, longitudinal, prospective French study conducted from September 2004 to September 2006. The main objectives were immuno-virological and clinical assessments during the treatment and after a 2 year follow-up. Secondary objectives were patient's characteristics, drug treatment modalities, safety and quality of life. RESULTS: During this period, 364 patients were included, their characteristics were as follow: mean age : 45 9 years, median viral load: 4,70 log10 copies/ml, median CD4 count : 155 cell/mm3; AIDS defining events : 52%; antiretroviral pre-treated patients: 97% since a mean of 10 3 years. These characteristics were similar to the HIV French Hospital database. At 24 months, 43% of treated patients had an undetectable HIV plasma viral load (threshold 400 copies/mL) and 39% had a CD4 increase of at least 100 cell/ mm3 (versus 27% and 32% respectively in the TORO trial). The most common adverse event was injection site reaction (93% versus 98% in TORO). In addition, the probability at 12 months of an AIDS defining events or patient death was 12% (IC95% [9%; 16%]). CONCLUSIONS: The ZOOM observational study confirmed, in real life setting, enfuvirtide safety and efficacy demonstrated in the TORO trials. It also shows that enfuvirtide drug treatment modalities follow the summary of product characteristics recommendations.
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